From a therapeutic standpoint, the current report also opens the door to explore whether targeting Nrf2 can improve therapeutic outcome for cancer patients by specifically blocking the Nrf2 activity on HIF1α, glycolysis and the stemness genes to eliminate CSCs. The gene discussed is NFE2L2; the disease is cancer.